|Age||70 YEARS OLD|
|Net Worth:||$8.2 Billion|
In 2005, Andreas Struengmann and twin brother Thomas sold their generic drugmaker Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion.
They cofounded Hexal in 1986. The company launched the highly successful cholesterol-lowering drug simvastatin, a substitute for Merck's ZOCOR.
The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.
Their portfolio includes Germany's BioNTech and Uruguay's Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.
In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
Andreas Strungmann Net Worth: Andreas Strungmann is a German pharmacist who has a net worth of $8.2 billion. Born in 1950, Andreas and his twin brother, Thomas, made their fortune as founders of Hexal AG, one of the leading generic producers in Germany. The medical doctor Andres left his medical practice in Africa; and again together with his brother, he founded generic drug producer Hexal AG in 1986. Two decades later, the brothers sold the company and their 68% share of Eon Labs of the U.S. to Novartis, which makes Sandoz the biggest generic drug company. Since then, through their Santo Holding, the twin duo has been investing in biotech sector focused on cancer research. Moreover, Andreas accepted an executive position at Sandoz at the age of 56.